
Liquidity, historical trends, and peer comparisons.
According to TG Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 4.27. This represents a change of -5.19% compared to the average of 4.50 of the last 4 quarters.
The mean historical Current Ratio of TG Therapeutics, Inc. over the last ten years is 4.16. The current 4.27 Current Ratio has changed 2.50% with respect to the historical average. Over the past ten years (40 quarters), TGTX's Current Ratio was at its highest in in the December 2020 quarter at 6.99. The Current Ratio was at its lowest in in the September 2019 quarter at 1.00.
Average
4.16
Median
3.72
Minimum
1.77
Maximum
6.99
Discovering the peaks and valleys of TG Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 295.60%
Maximum Annual Current Ratio = 6.99
Minimum Annual Increase = -63.48%
Minimum Annual Current Ratio = 1.77
| Year | Current Ratio | Change |
|---|---|---|
| 2025 | 4.10 | -34.32% |
| 2024 | 6.25 | 5.53% |
| 2023 | 5.92 | 87.12% |
| 2022 | 3.16 | -37.51% |
| 2021 | 5.06 | -27.55% |
| 2020 | 6.99 | 295.60% |
| 2019 | 1.77 | -13.17% |
| 2018 | 2.03 | -39.06% |
| 2017 | 3.34 | 10.76% |
| 2016 | 3.01 | -63.48% |
The current Current Ratio of TG Therapeutics, Inc. (TGTX) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
5.42
5-year avg
4.90
10-year avg
4.16
TG Therapeutics, Inc.’s Current Ratio is greater than Genmab A/S (2.46), less than Xencor, Inc. (6.39), less than Celldex Therapeutics, Inc. (11.82), greater than MacroGenics, Inc. (2.96), greater than ADC Therapeutics S.A. (3.03), less than Corvus Pharmaceuticals, Inc. (16.16), greater than Innate Pharma S.A. (0.60), less than Adagene Inc. (5.02),
| Company | Current Ratio | Market cap |
|---|---|---|
| 2.46 | $34.32B | |
| 6.39 | $2.20B | |
| 11.82 | $2.27B | |
| 2.96 | $157.02M | |
| 3.03 | $211.93M | |
| 16.16 | $815.97M | |
| 0.60 | $158.94M | |
| 5.02 | $86.22M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like TG Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like TG Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is TG Therapeutics, Inc.'s Current Ratio?
How is the Current Ratio calculated for TG Therapeutics, Inc. (TGTX)?
What is the highest Current Ratio for TG Therapeutics, Inc. (TGTX)?
What is the 3-year average Current Ratio for TG Therapeutics, Inc. (TGTX)?
What is the 5-year average Current Ratio for TG Therapeutics, Inc. (TGTX)?
How does the current Current Ratio for TG Therapeutics, Inc. (TGTX) compare to its historical average?